Respirology · 2019 · 19 citations · 30 references
PharmacyClinical SciencesPharmacotherapyPulmonary Function TestingPulmonologyRespiratory PharmacotherapyBronchodilator TherapyChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease CareChronic Obstructive Pulmonary Disease PharmacotherapyCombination Inhaler TherapyObstructive Lung DiseaseAdult Bronchodilator TherapyChronic Obstructive Pulmonary Disease BronchodilationLong-acting Bronchodilator TherapyLong-acting Muscarinic AntagonistsLung Function DeclineLung Function TestingMaintenance Bronchodilator TherapyMuscarinic Agonists
ABSTRACT Background and objective Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (q.d.) has demonstrated greater improvements in lung function, patient‐reported outcomes and lower exacerbation rates versus mono long‐acting muscarinic antagonists (LAMA) in chronic obstructive pulmonary disease (COPD) patients. However, data are limited on initial treatment with IND/GLY 110/50 μg q.d. versus mono LAMA in COPD patients, not previously on maintenance treatment with long‐acting bronchodilators (LABD). Methods A pooled analysis of ARISE, SHINE and SPARK trials was conducted to evaluate the efficacy of IND/GLY 110/50 μg q.d. versus open‐label (OL) tiotropium (TIO) 18 μg q.d. and GLY 50 μg q.d. in COPD patients, not on maintenance treatment with LABD at study entry (LABD‐naïve). Efficacy was assessed after 24/26 weeks of treatment. Results In total, 998 LABD‐naïve patients were included (IND/GLY: 353; OL TIO: 328; GLY: 317). Patients treated with IND/GLY 110/50 μg q.d. experienced greater improvements in trough forced expiratory volume in 1 s (FEV 1 ) versus OL TIO 18 μg q.d. (least squares mean treatment difference (Δ): 0.086 L) and GLY 50 μg q.d. (Δ: 0.080 L) after 24/26 weeks. Improvements in electronic diary (eDiary) symptom scores, transition dyspnoea index (TDI) focal score, St George's Respiratory Questionnaire (SGRQ) total score and rescue medication use were also greater with IND/GLY versus OL TIO and GLY. Greater proportion of patients achieved minimal clinically important difference in trough FEV 1 , TDI and SGRQ with IND/GLY versus OL TIO and GLY. Conclusion LABD‐naïve patients treated with IND/GLY 110/50 μg q.d. achieved improvements in lung function, daily symptoms, dyspnoea, health‐related quality of life and rescue medication use versus those who received single LAMA.
30
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease
Donald P. Tashkin, Bartolomé R. Celli, Stephen Senn et al. · New England Journal of Medicine · 2008 · 2.2K citations · Full text
Donald A. Mahler, David H. Weinberg, Carolyn K. Wells et al. · CHEST Journal · 1984 · 1.3K citations
Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD
Jadwiga A. Wedzicha, Donald Banerji, Kenneth R. Chapman et al. · New England Journal of Medicine · 2016 · 870 citations · Full text
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier, Bettina Hederer, Thomas Glaab et al. · New England Journal of Medicine · 2011 · 681 citations · Full text